ADA抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Raji cell lysate, Primary antibody: P07770(ADA Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07770(ADA Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07770(ADA Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

Anti-drug antibodies (ADAs) are immune proteins produced by the body in response to biologic therapies, such as recombinant proteins, monoclonal antibodies, or enzyme replacement therapies. These antibodies arise when the immune system recognizes therapeutic proteins as foreign antigens. ADA development can be influenced by factors like drug structure, patient genetics, dosing regimen, and route of administration.

ADAs are categorized as neutralizing or non-neutralizing. Neutralizing ADAs bind directly to the drug's active site, blocking its therapeutic function, while non-neutralizing ADAs may affect drug pharmacokinetics by accelerating clearance or forming immune complexes. Both types can compromise treatment efficacy, leading to reduced clinical response or loss of drug effect. In some cases, ADAs may trigger hypersensitivity reactions or autoimmune-like syndromes.

The detection and monitoring of ADAs are critical during drug development and clinical use. Techniques like ELISA, radioimmunoassay, or cell-based assays are employed to assess immunogenicity. Strategies to mitigate ADA formation include protein engineering to reduce immunogenic epitopes, optimizing dosing schedules, or co-administering immunosuppressants. However, ADA management remains challenging due to inter-patient variability in immune responses. Understanding ADA mechanisms is vital for improving biologic drug safety, efficacy, and personalized treatment approaches.